Switch to:
GuruFocus has detected 1 Warning Sign with Biomarin Pharmaceutical Inc $BMRN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
Biomarin Pharmaceutical Inc (NAS:BMRN)
Research & Development
$648 Mil (TTM As of Mar. 2017)

This is the expense the company spent on research and development. Biomarin Pharmaceutical Inc's research and development for the three months ended in Mar. 2017 was $145 Mil. Its research and development for the trailing twelve months (TTM) ended in Mar. 2017 was $648 Mil.


Definition

This is the expense the company spent on research and development.

Biomarin Pharmaceutical Inc Research & Development for the trailing twelve months (TTM) ended in Mar. 2017 was 167.039 (Jun. 2016 ) + 160.831 (Sep. 2016 ) + 175.242 (Dec. 2016 ) + 145.003 (Mar. 2017 ) = $648 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.


Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Related Terms

Gross Profit


Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

Biomarin Pharmaceutical Inc Annual Data

Dec07Dec08Dec09Dec10Dec11Dec12Dec13Dec14Dec15Dec16
Research & Development 7993115147214302355462635662

Biomarin Pharmaceutical Inc Quarterly Data

Dec14Mar15Jun15Sep15Dec15Mar16Jun16Sep16Dec16Mar17
Research & Development 142142158159176159167161175145
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK